Welcome to The Gersbach Lab at Duke University


Molecular and Cellular Engineering Applied to Regenerative Medicine and Gene Therapy

The Gersbach Lab is focused on engineering new methods for directing cell behavior to regenerate diseased or damaged tissues and treat genetic diseases.  We are particularly interested in developing and applying technologies that manipulate cellular processes at the genetic level.  Our work capitalizes on the products of the Genomic Revolution and modern advances in the fields of genetic reprogramming, gene delivery, protein engineering, stem cell transplantation, and synthetic  biology to create innovative biologic approaches to improving human health.  These studies also facilitate a better understanding of complex processes including organogenesis, cell lineage determination, and gene regulation that will ultimately lead to i mproved design of drugs and biotherapeutics.  Our efforts are catalyzed by interdisciplinary collaborations with investigators in engineering and medicine at Duke and other institutions.

 

    

               

   

 

 


Current News

April 7, 2015 - Isaac's paper is highlighted in NatureThe ScientistGenetic Engineering and Biotechnology News, and Duke.

April 6, 2015 - Isaac's paper on epigenome editing with a CRISPR/Cas9-based acetyltransferase is published in Nature Biotechnology.

April 6, 2015 - Our collaborative work with the Crawford and West labs in studying chromatin accessbility of neuronal enhancers is published in Nature Neuroscience.

March 23, 2015 - Lauren successfully defends her thesis - Congratulations Dr. Polstein Toth!

March 23, 2015 - Feimei is accepted into the Summer Scholar program through the Duke Center for Genomic and Computational Biology. Congrats Feimei! 

March 10, 2015 - Dave's paper is highlighted by Nature Reviews Neurology.

March 10, 2015 - Ami successfully defends her thesis - Congratulations Dr. Kabadi!

March 7, 2015  - Lauren's paper on light-inducible CRISPR-based gene regulation is highlighted in Biotechniques.

February 27, 2015  - The Muscular Dystrophy Association releases statements on our work using CRISPR/Cas9 technology for gene therapy for Duchenne muscular dystrophy here and here.

More News